All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On the 15th May 2017, Glenmark Pharmaceuticals’ bi-specific antibody (GBR 1342) was cleared by the U.S. Food and Drug Administration (FDA) for further investigation in phase I trials of Multiple Myeloma (MM) patients, who have received prior treatment. The trial will assess dose escalation and safety.
GBR 1342 is a modality developed using Glenmark’s BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) technology, which has optimized engineering features, such as compatibility with standard production processes and high production yields, as well as low immunogenic potential and the ability to modify Fc-mediated effector function.
Specifically, GBR 1342 uses a CD3 arm to engage cytotoxic T cells, then directs them towards the malignant myeloma cells using a second CD38 binding arm, therefore harnessing the patient’s own immune system to target the myeloma cells. Several bi-specific antibodies have recently been reported but are still in the early development phase, so this is very much a positive step forward.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox